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DNA damage induced apoptosis suppressor (DDIAS), or human
Noxin (hNoxin), is strongly expressed in lung cancers. DDIAS
knockdown induced apoptosis in non-small cell lung carcinoma
A549 cells in response to DNA damage, indicating DDIAS as a
potential therapeutic target in lung cancer. To understand the
transcriptional regulation of DDIAS, we determined the transcrip-
tion start site, promoter region, and transcription factor. We found
that DDIAS transcription begins at nucleotide 212 upstream of the
DDIAS translation start site. We cloned the DDIAS promoter region
and identiﬁed NFAT2 as a major transcription factor (Im et al., 2016
[1]). We demonstrated that NFATc1 regulates DDIAS expression in
both pancreatic cancer Panc-1 cells and lung cancer cells.
& 2015 The Authors. Published by Elsevier Inc. This is an open
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 These data provide information regarding the transcription site and promoter used to control
DDIAS transcription.
 NFATc1 plays a crucial role in DDIAS transcription in lung cancer cells.
 NFATc1 also controls DDIAS expression in the pancreatic cancer cell line PANC-1, as demonstrated
by growth inhibition in a knockdown model.1. Data
A 50-rapid ampliﬁcation of cDNA ends (RACE) assay revealed a transcription start site located 212
nucleotides upstream of the DDIAS translation start site or 32 base pairs (bp) downstream of the site
reported in the National Center for Biotechnology Information (NCBI) database (Fig. 1). This tran-
scription start site was conﬁrmed via RNA polymerase binding in a chromatin immunoprecipitation
(ChIP) assay (Fig. 2). Putative transcription factor binding sites are located in the P3 region of the
DDIAS promoter (Fig. 3A). In a P3-luciferase reporter assay, only NFATc1 knockdown signiﬁcantly
suppressed the promoter activity (Fig. 3B and C). DDIAS mRNA expression was found to be regulated
by NFAT signaling, as shown by treatment with cyclosporine A (CsA), a calcineurin inhibitor, phorbol
12-myristate 13-acetate (PMA), and the calcium ionophore A23187 (Fig. 4). Treatment with PMA
andA23187 increased the cellular expression of DDIAS mRNA (Fig. 4A). In contrast, the cellular DDIAS
mRNA level decreased after treatment with CsA (Fig. 4B). Previously, we showed that DDIAS knock-
down inhibits the growth of lung cancer cells [2]. In the pancreatic cancer cell line PANC-1, NFATc1
knockdown clearly induces DDIAS depletion and results in growth inhibition, indicating the NFATc1-
mediated control of DDIAS expression (Fig. 5).2. Experimental design, materials and methods
2.1. Determination of the transcription start site using 50 rapid ampliﬁcation of cDNA ends (RACE) in
HEK293 cells
To identify the 50 UTR of human DDIAS, 50 RACE was performed using the SMART RACE cDNA
Ampliﬁcation Kit (Clontech, Mountain View, CA, USA) according to the manufacturer's protocol. First-
strand cDNA was synthesized using RNA from human embryonic kidney 293 (HEK293) cells. 50-RACE
Fig. 2. ChIP assay of RNA polymerase (ser5) in HEK293 cells. RNA polymerase II (phospho-ser5) binding to the DDIAS promoter
in HEK293 cells. A ChIP assay was performed using an anti-RNA pol II antibody. An anti-IgG antibody was used as a negative
control. PCR ampliﬁcation was performed using the indicated DDIAS promoter-speciﬁc primers or control primers speciﬁc for
GAPDH.
Fig. 1. Determination of the transcription start site of DDIAS promoter. The transcription start site determined by 50-RACE is
32 bp downstream of the site reported by the NCBI database.
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mers: R1; 50-TGTACCTGTGCAAACCAGTGGCAGT-30 or R2; 50-AAAGCCTGCAATACCTGGGTCTGGT-30. The
PCR products were separated by electrophoresis on 1.5% agarose gels. After puriﬁcation using the
QIAquick Gel Extraction Kit (Qiagen, Valencia, CA, USA). PCR products were subcloned into the pGEM-
T vector using the TA Cloning Kit (Promega, Madison, WI, USA) and sequenced. The ﬁrst base pair
after the adapter was identiﬁed as the transcription start site of the human DDIAS gene [1].
Fig. 3. Putative transcription factor binding sites at P3 of the DDIAS promoter in HEK293 cells. (A) Putative transcription
binding sites at P3 of the DDIAS promoter. (B–C) The effects of putative transcription factor knockdown were examined using a
luciferase reporter assay (B); DDIAS mRNA and protein expression were evaluated using RT-PCR and Western blotting,
respectively (C). HEK293 cells were transfected with siRNAs for SP1, cJun, and cMyc; scrambled siRNA was used as a control. All
data are shown as means7standard errors of the mean (S.E.M).
Fig. 4. Regulation of DDIAS expression by NFAT in HEK293 cells. DDIAS mRNA level was examined after treatment of cells with
PMA and A23187 (A) or CsA treatment (B).
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HEK293, non-small cell lung cancer cell NCI-H1703, and pancreatic cancer cell Panc-1 cells were cul-
tured in an incubator at 37 °C and 5% CO2. HEK293 and Panc-1 cells were cultured in Dulbecco's modiﬁed
Eagle's medium (DMEM); NCI-H1703 cells were cultured in RPMI-1640 containing 10% fetal bovine serum
(FBS), 50 U/mL of penicillin, and 50 μg/mL of streptomycin (Invitrogen, USA). Cells were transfected with
40 nM siRNAs with Lipofectamine 2000 (Invitrogen, USA) according to the manufacturer's instructions.
siRNA sequences were as follows: siSP1, 50-CUUUUUCACCAAUGCCAAU-30, sicJun: 50-CAAGAAGAUGCGCC
GCAAC-30, sicMyc: 50-GUCAAGAGGCGAACACACA-30, siNFATc1: 50-GGACUCCAAGGUCAUUUUC-30, siDDIAS
D1: 50-GCCUAUCAUUUCCCUGAUC-30, siDDIAS D2: 50-CUGUAACCCAGGCAGAUGU-30, or siScrambled: 50-
CCUACGCCACCAAUUUCGU-30.2.3. Luciferase reporter assays
Cells were co-transfected with the DDIAS promoter (1205) and pRL-TK, using 2 μl of Polyfect
(Qiagen, USA) per well. Cells were harvested 36 h after transfection and lysed in 1 passive lysis
buffer. Fireﬂy and Renilla luciferase activities were assayed using a dual-luciferase reporter assay
system (Promega, USA) and a luminometer (Victor X Light; Perkin Elmer, USA). Fireﬂy luciferase
activity was normalized to Renilla luciferase activity and expressed as the relative luciferase activity
(RLA) to reﬂect promoter activity.
Fig. 5. Effect of NFATc1 knockdown on DDIAS expression and cell growth in Panc-1 cells. Cells were transfected with siNFATc1
to induce NFATc1 knockdown. (A) Cell growth was determined after NFATc1 knockdown (siNFATc1 treatment for 96 h) using an
SRB assay. All data are shown as means7S.E.M. **po0.01. (B) The effect of DDIAS knockdown on cell growth determined by an
SRB assay at 72 h. All data are shown as mean7S.E.M. *po0.05 or **po0.01.
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Total RNA was extracted from cells using TRIzol (Invitrogen) and was reverse-transcribed into
cDNA using TOPscript™ RT DryMIX (dT18) (Enzynomics, Daejeon, Korea) according to the manu-
facturer's instructions. The cycling conditions were 95 °C for 5 min, 95 °C for 30 s, 55 °C for 30 s, and
72 °C for 30 s. The following primers were used: NFATc1 F, 50-GGGTTAAGTCCTCTCCCAAG-30; R, 50-
GGGTTAAGTCCTCTCCCAAG-30; DDIAS F, 50-CTTGCAGCAGTTGTTACGAA-30; R, 50-GTGACCAAGCACTTC-
GAGTT-30; GAPDH F, 50-TCATGACCACAGTCCATGCC-30; R, 50-TCCACCACCCTGTTGCTGTA-30.
2.5. Chromatin immunoprecipitation (ChIP) assay
ChIP assays were performed as previously described [3]. Cells were lysed and sonicated. The
chromatin solution was incubated with 2 μg of anti-RNA polymerase II (phosphor-Ser5, 05-623B) or
normal mouse immunoglobulin G (IgG; negative control, 12-371B) from ChIP assay kit (17-371,
Millipore, USA) overnight at 4 °C. These isolated DNA fragments were subsequently used as templates
for a PCR analysis. Primers were used to amplify the putative NFAT consensus binding sites located in
the DDIAS promoter region. The primers were as follows: forward for DDIAS, 50-AAAAGGAGGC-
CAGCAGAAGCGC-30; reverse for DDIAS, 50- CCGCGTCCTTTTCCGCCGGAA-30; forward for GAPDH, 50-
TACTAGCGGTTTTACGGGCG-30; reverse for GAPDH, 50-TCGAACAGGAGGAGCAGAGAGCGA -30.
2.6. Immunoblotting assays
Cells were lysed with 1X RIPA buffer (Millipore) containing 1 mM Na3VO4, 1 mM sodium ﬂuoride,
1 mM PMSF, and protease inhibitor cocktail (Roche, Switzerland). The lysates were quantiﬁed using a
BCA assay kit (Bio-Rad, USA) and subjected to immunoblotting with speciﬁc antibodies, as follows:
anti-SP1 (5931) or anti-cJun (9165) from Cell Signaling Technology (Beverly, USA), anti-cMyc (sc-40)
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PA0212) from AbFrontier (Seoul, Korea). Antibodies were diluted in 5% BSA in phosphate-buffered
saline containing 0.1% Tween 20 (PBS-T) overnight at 4 °C. After washing three times in PBS-T for
10 min, membranes were incubated for 1 h with horseradish peroxidase-labeled goat anti-mouse IgG
(LF-SA8001) or goat anti-rabbit IgG (LF-SA8002) from AbFrontier and washed three times in PBS-T for
10 min. Western blot signals were detected using an enhanced chemiluminescence (ECL) kit
(Millipore).
2.7. Cell viability
Cell viability was determined using the sulforhodamine B assay, as previously described [4]. The
amount of sulforhodamine B dye bound to the cell matrix was quantiﬁed using a spectrophotometer
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